Passage Bio Stock Analysis
| PASG Stock | USD 10.57 0.42 3.82% |
Passage Bio holds a debt-to-equity ratio of 0.11. Passage Bio's financial risk is the risk to Passage Bio stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Passage Bio's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Passage Bio's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Passage Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Passage Bio's stakeholders.
For many companies, including Passage Bio, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Passage Bio, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Passage Bio's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Passage Bio's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Passage Bio is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Passage Bio to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Passage Bio is said to be less leveraged. If creditors hold a majority of Passage Bio's assets, the Company is said to be highly leveraged.
Passage Bio is undervalued with Real Value of 18.38 and Hype Value of 11.16. The main objective of Passage Bio stock analysis is to determine its intrinsic value, which is an estimate of what Passage Bio is worth, separate from its market price. There are two main types of Passage Bio's stock analysis: fundamental analysis and technical analysis.
The Passage Bio stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Passage Bio's ongoing operational relationships across important fundamental and technical indicators.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Passage Stock Analysis Notes
About 52.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.15. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Passage Bio recorded a loss per share of 13.58. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 14th of July 2025. Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Passage Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people. To find out more about Passage Bio contact William MD at 267 866 0311 or learn more at https://www.passagebio.com.Passage Bio Investment Alerts
| Passage Bio is way too risky over 90 days horizon | |
| Passage Bio appears to be risky and price may revert if volatility continues | |
| Passage Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (64.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Passage Bio currently holds about 239.25 M in cash with (47.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39. | |
| Passage Bio has a frail financial position based on the latest SEC disclosures |
Passage Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 34.93 M.Technical Drivers
As of the 4th of February, Passage Bio holds the Risk Adjusted Performance of 0.1069, coefficient of variation of 752.48, and Semi Deviation of 6.35. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Passage Bio, as well as the relationship between them. Please check Passage Bio information ratio, value at risk, as well as the relationship between the Value At Risk and expected short fall to decide if Passage Bio is priced some-what accurately, providing market reflects its current price of 10.57 per share. Given that Passage Bio has jensen alpha of 0.8582, we recommend you to check out Passage Bio's recent market performance to make sure the company can sustain itself at a future point.Passage Bio Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Passage Bio middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Passage Bio. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Passage Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Passage Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Passage Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Passage Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Passage Bio Outstanding Bonds
Passage Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Passage Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Passage bonds can be classified according to their maturity, which is the date when Passage Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Passage Bio Predictive Daily Indicators
Passage Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Passage Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 2543.04 | |||
| Daily Balance Of Power | (0.47) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 10.86 | |||
| Day Typical Price | 10.76 | |||
| Price Action Indicator | (0.50) | |||
| Period Momentum Indicator | (0.42) | |||
| Relative Strength Index | 47.6 |
Passage Bio Forecast Models
Passage Bio's time-series forecasting models are one of many Passage Bio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Passage Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Passage Bio Bond Ratings
Passage Bio financial ratings play a critical role in determining how much Passage Bio have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Passage Bio's borrowing costs.| Piotroski F Score | 3 | Frail | View |
| Beneish M Score | (5.14) | Unlikely Manipulator | View |
Passage Bio Debt to Cash Allocation
Many companies such as Passage Bio, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Passage Bio currently holds 25.48 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Passage Bio has a current ratio of 9.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Passage Bio's use of debt, we should always consider it together with its cash and equity.Passage Bio Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Passage Bio's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Passage Bio, which in turn will lower the firm's financial flexibility.Passage Bio Corporate Bonds Issued
Most Passage bonds can be classified according to their maturity, which is the date when Passage Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About Passage Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Passage Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Passage shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Passage Bio. By using and applying Passage Stock analysis, traders can create a robust methodology for identifying Passage entry and exit points for their positions.
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Passage Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Passage Bio to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Manager Now
Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital |
| All Next | Launch Module |
Complementary Tools for Passage Stock analysis
When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |